Fax: (011) 81-942-31-7699
Expression of tumor rejection antigens in colorectal carcinomas
Article first published online: 15 MAR 2002
Copyright © 2002 American Cancer Society
Volume 94, Issue 6, pages 1636–1641, 15 March 2002
How to Cite
Sasatomi, T., Suefuji, Y., Matsunaga, K., Yamana, H., Miyagi, Y., Araki, Y., Ogata, Y., Itoh, K. and Shirouzu, K. (2002), Expression of tumor rejection antigens in colorectal carcinomas. Cancer, 94: 1636–1641. doi: 10.1002/cncr.10421
- Issue published online: 15 MAR 2002
- Article first published online: 15 MAR 2002
- Manuscript Accepted: 26 OCT 2001
- Manuscript Revised: 24 OCT 2001
- Manuscript Received: 27 NOV 2000
- Grant-in-Aid from the Ministry of Education, Science, Sports, and Culture of Japan. Grant Numbers: 08266266, 09470271, 10153265, 09770985, 10671230, 09671401
- Health Science Research Grant for Research on the Human Genome and Gene Therapy from the Ministry of Health and Welfare of Japan
- colorectal carcinoma;
- cytotoxic T lymphocytes;
- peripheral blood mononuclear cells;
The authors recently reported that the SART2 and SART3 antigens encode tumor epitopes recognized by HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes (CTLs) established from esophageal carcinoma patients. The current study investigated these antigens to explore a potential molecule for specific immunotherapy for colorectal carcinoma patients.
The SART2 and SART3 antigens were investigated by Western blotting in colorectal carcinoma cell lines and in cancer tissues. For induction of CTLs, peripheral blood mononuclear cells (PBMCs) of HLA A-24-positive cancer patients were stimulated in vitro with peptides.
The 140 kD SART3 antigen was expressed in both the cytosol and nuclear fractions of all six colon carcinoma cell lines, 27 of 41 (65.9%) cytosol fractions, 30 of 41 (73.2%) nuclear fractions of colorectal carcinoma tissue samples, and in 0 of 7 non-tumorous tissues. The 100 kD SART2 antigen was expressed in the cytosol fractions of 2 of 6 colon carcinoma cell lines, 5 of 20 (25%) cytosol fractions of colorectal carcinoma tissue samples, and in 0 of 7 non tumorous tissues. HLA-A24-restricted CTLs cytotoxic to colon carcinoma cells were induced from PBMCs of colon carcinoma patients by stimulation with the two immunogenic peptides of SART3.
The SART3 antigen could be an appropriate target molecule for specific immunotherapy for colorectal carcinoma patients. Cancer 2002;94:1636–41. © 2002 American Cancer Society.